A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease

European Journal of Neurology

Volumn 5, Issue 3, 1998, Pages 235-242

  Wermuth, L ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

L dopa; Parkinson's disease; Pramipexole

Indexed keywords

DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PRAMIPEXOLE;

ADULT; AGED; AKINESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSKINESIA; DYSTONIA; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; VERTIGO;

EID: 0031832130     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.1998.530235.x     Document Type: Article

References (17)

1. Brown AS, Gershow S (1993). Dopamine and depression. J Neurol Transmission 91:75-109.
2. Calne DB (1993). Treatment of Parkinson's disease. NEJM 329:1021-1027.
3. Cummings JL (1992). Depression and Parkinson's disease: a review. Am J Psychiatry 49:443-454.
4. Fahn S (1989). Adverse effects of levodopa in Parkinson's disease. In: Drugs for the Treatment of Parkinson's Disease, Calne DB (editor). Berlin: Springer, pp. 385-409.
5. Fahn S (1992). Adverse effect of levodopa. In: The Scientific Basis for the Treatment of Parkinson's Disease, Olanow CW, Lieberman AN (editors). Carnforth, England: Parthenon Publishing Group, pp. 809-812.
6. Guy W (1976). Abnormal involuntary movement scale. In: ECDEU Assessment Manual. Rockville, MD: US Department of Health Education and Welfare, National Institute of Health Education and Welfare, National Institute of Mental Health, pp. 534-538.
7. Hoehn MM, Yahr MD (1967). Parkinsonism: onset, progression and mortality. Neurology 17:427-442.
8. Hornykiewicz O (1989). The neurochemical basis of the pharmacology of Parkinson's disease. Handbook Exp Pharmacol 88:185-204.
9. Hyslop DK, Hoffman WE, Smith MW, Piercey MF (1993). Excitation of anterior caudate neurons by stimulation of D3 receptors. Neurosci Abstr 19:80.
10. Karch FF, Lasagna L (1975). Adverse drug reactions. A critical review. JAMA 234:1236-1241.
11. Mierau J, Schingnitz G (1992). Biochemical and pharmacological studies on SND 919 CL 2 Y, a potent and selective dopamine D2-receptor agonist. Eur J Pharmacol 215: 161-170.
12. Muenter MD, Tyce GM (1971). L-dopa therapy of Parkinson's disease: Plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 46:231-239.
13. Olanow CW (1988). Single-blind observer-controlled study of carbodopa/levodopa vs BCT in untreated Parkinson's disease. Arch Neurol 45:206.
14. Olanow CW (1990). Oxidation reactions in Parkinson's disease. Neurol 40:32-39.
15. Olanow CW (1992). An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 32:S2-S9.
16. Rascol A, Monstastruc JL, Guiraud-Chaumeil B, and Clanet M (1982). BCT as the first treatment of Parkinson's disease: long-term results. Rev Neurol 138: 401-408.
17. 3-preferring (Pramipexole) agonist in mice and rats. Neurosci Abstr 20:827.